Long-term use of budesonide effective in microscopic colitis: ACG

Published On 2022-05-12 14:00 GMT   |   Update On 2022-05-12 14:01 GMT

Long-term use of budesonide in microscopic colitis (MC) appears to be effective, according to a recent study published in The American Journal of Gastroenterology The outcomes and safety of budesonide maintenance therapy in microscopic colitis (MC) are not well known. Adult residents of Olmsted County, Minnesota diagnosed with MC (2002-2019) and treated with budesonide...

Login or Register to read the full article

Long-term use of budesonide in microscopic colitis (MC) appears to be effective, according to a recent study published in The American Journal of Gastroenterology

The outcomes and safety of budesonide maintenance therapy in microscopic colitis (MC) are not well known. Adult residents of Olmsted County, Minnesota diagnosed with MC (2002-2019) and treated with budesonide were identified using the Rochester Epidemiology Project. The response was assessed at 12 +/- 4 weeks after initiation of therapy and defined as complete (resolution of diarrhoea), partial (≥50% improvement in a number of bowel movements), nonresponse (<50% improvement), and intolerance (discontinued due to side-effects). For safety outcomes, cases (budesonide maintenance) and MC controls (no budesonide therapy) were matched by gender and age at diagnosis (+/-2 years).

The results of the study are:

  • A total of 450 patients were identified, of which 162 (36.0%) were treated with budesonide for induction of clinical remission
  • Clinical outcomes for induction were as follows: 130 (80.2%) complete response, 22 (13.6%) partial response, 8 (4.9%) no response, and 2 (1.2%) intolerance. After induction, 96 (63.2%) had recurrence after discontinuation; 27 (28.1%) required further budesonide induction treatment without maintenance, 56 (58.3%) required long-term budesonide maintenance, and 13 (13.5%) were treated with other therapies.
  • Of those receiving budesonide maintenance, all responded [55 (98.2%) complete, 1 (1.8%) partial].
  • No patient stopped maintenance from adverse events. The median duration of follow-up was 5.6 years (0.3-18.9).
  • There was no significant difference between cases and controls in the incidence of osteopenia/ osteoporosis, diabetes mellitus, hypertension, glaucoma, or cataracts.

Thus, the long-term use of budesonide in MC appears to be effective and generally well tolerated with limited adverse effects.

Reference:

Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile from a Population-Based Study by Tome, June et al. published in The American Journal of Gastroenterology.

doi: 10.14309/ajg.0000000000001774

Keywords:

Budesonide, Maintenance, Microscopic Colitis, Clinical Outcomes, Safety Profile, Population-Based Study, Tome, June Sehgal, Kanika Kamboj, Amrit K. Comstock, Bryce, Harmsen, William S. Khanna, Sahil, Pardi, Darrell S., The American Journal of Gastroenterology


Tags:    
Advertisement
Article Source : the American College of Gastroenterology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News